Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an update.
CanSino Biologics Inc. has announced a board meeting scheduled for October 27, 2025, to review and approve the company’s third quarterly results for the period ending September 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$66.60 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of vaccines. The company is known for its innovative approaches in the biopharmaceutical industry, particularly in vaccine development.
Average Trading Volume: 2,301,521
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.9B
Find detailed analytics on 6185 stock on TipRanks’ Stock Analysis page.